NicOx Revenue and Competitors

Valbonne,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • NicOx's estimated annual revenue is currently $14.7M per year.(i)
  • NicOx's estimated revenue per employee is $201,000

Employee Data

  • NicOx has 73 Employees.(i)
  • NicOx grew their employee count by 14% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$41.8M20816%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$23.9M1190%N/AN/A
#5
$108.1M49324%N/AN/A
#6
$52.9M26313%N/AN/A
#7
$24.7M12313%N/AN/A
#8
$1.8M1813%$114.3MN/A
#9
$9M457%N/AN/A
#10
$14.7M73-11%N/AN/A
Add Company

Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform. For more information please visit www.nicox.com

keywords:N/A

N/A

Total Funding

73

Number of Employees

$14.7M

Revenue (est)

14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NicOx's People

NameTitleEmail/Phone
1
VP and Head Clinical Development
2
Chief Scientific Officer
3
VP finance
4
Director Clinical Operations
5
Director, Pharmaceutical Development & CMC
6
Clinical Team Lead
7
Sr. Director, R&D Project Management
8
EVP and Chief Business Officer | Number two to the CEO
9
Financial and Legal Department Assistant
10
HR Senior Group Manager

NicOx News

2022-04-20 - Nicox Reports 2021 Financial Results and First Quarter 2022 ...

said Michele Garufi, Chief Executive Officer of Nicox. Key UpcomingMilestone. Mont Blanc Phase 3 clinical trial on NCX 470 in glaucoma:...

2022-04-13 - Nicox (OTCMKTS:NICXF) Upgraded to “Buy” at Zacks ...

Nicox (OTCMKTS:NICXF) Upgraded to “Buy” at Zacks Investment Research. Posted by admin on Apr 19th, 2022. Share on Twitter Share on Facebook Share on...

2022-04-06 - Nicox's NCX 470 Dolomites Phase 2 Results Published in ...

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the results from its Dolomites...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$48.1M2386%N/A
#2
$92.4M32628%N/A